1. Home
  2. LRE vs SCYX Comparison

LRE vs SCYX Comparison

Compare LRE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRE
  • SCYX
  • Stock Information
  • Founded
  • LRE 2001
  • SCYX 1999
  • Country
  • LRE Japan
  • SCYX United States
  • Employees
  • LRE N/A
  • SCYX N/A
  • Industry
  • LRE
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LRE
  • SCYX Health Care
  • Exchange
  • LRE Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • LRE 24.0M
  • SCYX 27.3M
  • IPO Year
  • LRE 2023
  • SCYX 2014
  • Fundamental
  • Price
  • LRE $1.65
  • SCYX $0.68
  • Analyst Decision
  • LRE
  • SCYX
  • Analyst Count
  • LRE 0
  • SCYX 0
  • Target Price
  • LRE N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • LRE 8.5K
  • SCYX 205.2K
  • Earning Date
  • LRE 01-01-0001
  • SCYX 08-11-2025
  • Dividend Yield
  • LRE N/A
  • SCYX N/A
  • EPS Growth
  • LRE N/A
  • SCYX N/A
  • EPS
  • LRE N/A
  • SCYX N/A
  • Revenue
  • LRE $110,330,328.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • LRE N/A
  • SCYX $410.22
  • Revenue Next Year
  • LRE N/A
  • SCYX $248.83
  • P/E Ratio
  • LRE N/A
  • SCYX N/A
  • Revenue Growth
  • LRE 3.92
  • SCYX N/A
  • 52 Week Low
  • LRE $1.10
  • SCYX $0.66
  • 52 Week High
  • LRE $2.49
  • SCYX $2.13
  • Technical
  • Relative Strength Index (RSI)
  • LRE 41.55
  • SCYX 38.69
  • Support Level
  • LRE $1.61
  • SCYX $0.68
  • Resistance Level
  • LRE $1.85
  • SCYX $0.74
  • Average True Range (ATR)
  • LRE 0.09
  • SCYX 0.03
  • MACD
  • LRE -0.03
  • SCYX -0.00
  • Stochastic Oscillator
  • LRE 7.41
  • SCYX 4.07

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: